217-IL) inhibits IL‑1 beta secretion in LPS-activated human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner (orange line), as measured by the Human IL‑1 beta /IL‑1F2 Quantikine ELISA Kit (Catalog #
DLB50). IL‑1 beta secretion inhibited by Recombinant Human IL‑10 (0.25 ng/mL) is neutralized (green line) by increasing concentrations of Human IL‑10 Ra Monoclonal Antibody (Catalog # MAB274). The ND
50 is typically 0.03-0.1 µg/mL in the presence of LPS (0.25 ng/mL)." class="big_lightbox">

217-IL) inhibits IL‑1 beta secretion in LPS-activated human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner (orange line), as measured by the Human IL‑1 beta /IL‑1F2 Quantikine ELISA Kit (Catalog #
DLB50). IL‑1 beta secretion inhibited by Recombinant Human IL‑10 (0.25 ng/mL) is neutralized (green line) by increasing concentrations of Human IL‑10 Ra Monoclonal Antibody (Catalog # MAB274). The ND
50 is typically 0.03-0.1 µg/mL in the presence of LPS (0.25 ng/mL)." alt="Recombinant Human IL‑10 (Catalog #
217-IL) inhibits IL‑1 beta secretion in LPS-activated human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner (orange line), as measured by the Human IL‑1 beta /IL‑1F2 Quantikine ELISA Kit (Catalog #
DLB50). IL‑1 beta secretion inhibited by Recombinant Human IL‑10 (0.25 ng/mL) is neutralized (green line) by increasing concentrations of Human IL‑10 Ra Monoclonal Antibody (Catalog # MAB274). The ND
50 is typically 0.03-0.1 µg/mL in the presence of LPS (0.25 ng/mL)." class="big_thumb" />